These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 2527249

  • 1. Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor.
    Hirsch AT, Dzau VJ, Majzoub JA, Creager MA.
    J Clin Invest; 1989 Aug; 84(2):418-26. PubMed ID: 2527249
    [Abstract] [Full Text] [Related]

  • 2. Biphasic forearm vascular responses to intraarterial arginine vasopressin.
    Suzuki S, Takeshita A, Imaizumi T, Hirooka Y, Yoshida M, Ando S, Nakamura M.
    J Clin Invest; 1989 Aug; 84(2):427-34. PubMed ID: 2547832
    [Abstract] [Full Text] [Related]

  • 3. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
    Naitoh M, Suzuki H, Murakami M, Matsumoto A, Ichihara A, Nakamoto H, Yamamura Y, Saruta T.
    Am J Physiol; 1993 Oct; 265(4 Pt 2):R934-42. PubMed ID: 8238468
    [Abstract] [Full Text] [Related]

  • 4. V2 receptor-mediated vasodilation in healthy humans.
    Tagawa T, Imaizumi T, Shiramoto M, Endo T, Hironaga K, Takeshita A.
    J Cardiovasc Pharmacol; 1995 Mar; 25(3):387-92. PubMed ID: 7769802
    [Abstract] [Full Text] [Related]

  • 5. Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels.
    Tagawa T, Imaizumi T, Endo T, Shiramoto M, Hirooka Y, Ando S, Takeshita A.
    J Clin Invest; 1993 Sep; 92(3):1483-90. PubMed ID: 8376600
    [Abstract] [Full Text] [Related]

  • 6. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation.
    Aki Y, Tamaki T, Kiyomoto H, He H, Yoshida H, Iwao H, Abe Y.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):331-6. PubMed ID: 7511766
    [Abstract] [Full Text] [Related]

  • 7. Renal versus hindquarter hemodynamic responses to vasopressin in conscious rats.
    Harrison-Bernard LM, Brizzee BL, Clifton GG, Walker BR.
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):719-26. PubMed ID: 1703592
    [Abstract] [Full Text] [Related]

  • 8. Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors.
    Feng JJ, Arendshorst WJ.
    Am J Physiol; 1996 Aug; 271(2 Pt 2):F304-13. PubMed ID: 8770161
    [Abstract] [Full Text] [Related]

  • 9. Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs.
    Liard JF.
    Am J Physiol; 1990 Feb; 258(2 Pt 2):H482-9. PubMed ID: 2137987
    [Abstract] [Full Text] [Related]

  • 10. Effects of arginine vasopressin and 1-desamino-8-D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect.
    van Lieburg AF, Knoers NV, Monnens LA, Smits P.
    J Hypertens; 1995 Dec; 13(12 Pt 2):1695-700. PubMed ID: 8903635
    [Abstract] [Full Text] [Related]

  • 11. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors.
    Walker BR, Childs ME, Adams EM.
    Am J Physiol; 1988 Aug; 255(2 Pt 2):H261-5. PubMed ID: 2970231
    [Abstract] [Full Text] [Related]

  • 12. V1- and V2-receptor contributions to ovine fetal renal and cardiovascular responses to vasopressin.
    Ervin MG, Ross MG, Leake RD, Fisher DA.
    Am J Physiol; 1992 Apr; 262(4 Pt 2):R636-43. PubMed ID: 1566929
    [Abstract] [Full Text] [Related]

  • 13. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans.
    Weber R, Pechère-Bertschi A, Hayoz D, Gerc V, Brouard R, Lahmy JP, Brunner HR, Burnier M.
    Hypertension; 1997 Nov; 30(5):1121-7. PubMed ID: 9369265
    [Abstract] [Full Text] [Related]

  • 14. Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists.
    Ohlstein EH, Berkowitz BA.
    J Pharmacol Exp Ther; 1986 Dec; 239(3):737-41. PubMed ID: 2948008
    [Abstract] [Full Text] [Related]

  • 15. AVP-induced pulmonary vasodilation during specific V1 receptor block in conscious dogs.
    Nyhan DP, Clougherty PW, Murray PA.
    Am J Physiol; 1987 Sep; 253(3 Pt 2):H493-9. PubMed ID: 2888317
    [Abstract] [Full Text] [Related]

  • 16. Evidence for a vasodilatory effect of vasopressin in the conscious rat.
    Walker BR.
    Am J Physiol; 1986 Jul; 251(1 Pt 2):H34-9. PubMed ID: 3755295
    [Abstract] [Full Text] [Related]

  • 17. Pulmonary vasodilatory response to neurohypophyseal peptides in the rat.
    Russ RD, Resta TC, Walker BR.
    J Appl Physiol (1985); 1992 Aug; 73(2):473-8. PubMed ID: 1399968
    [Abstract] [Full Text] [Related]

  • 18. Arginine vasopressin (AVP) replacement of helper cell requirement in IFN-gamma production. Evidence for a novel AVP receptor on mouse lymphocytes.
    Torres BA, Johnson HM.
    J Immunol; 1988 Apr 01; 140(7):2179-83. PubMed ID: 2965181
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
    Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ.
    J Pharmacol Exp Ther; 2011 Jun 01; 337(3):786-96. PubMed ID: 21411496
    [Abstract] [Full Text] [Related]

  • 20. Effect of V2-receptor-mediated changes on inner medullary blood flow induced by AVP.
    Kiberd B, Robertson CR, Larson T, Jamison RL.
    Am J Physiol; 1987 Sep 01; 253(3 Pt 2):F576-81. PubMed ID: 2957929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.